Patents by Inventor Toshimitsu Uede
Toshimitsu Uede has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10370450Abstract: The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.Type: GrantFiled: November 19, 2014Date of Patent: August 6, 2019Assignee: National University Corporation Hokkaido UniversityInventors: Daisuke Fujikura, Toshimitsu Uede
-
Publication number: 20160289331Abstract: The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.Type: ApplicationFiled: November 19, 2014Publication date: October 6, 2016Applicant: NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITYInventors: Daisuke Fujikura, Toshimitsu UEDE
-
Patent number: 9040295Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.Type: GrantFiled: January 16, 2013Date of Patent: May 26, 2015Assignee: Gene Techno Science Co., Ltd.Inventors: Shigeyuki Kon, Toshimitsu Uede
-
Patent number: 8901280Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.Type: GrantFiled: October 25, 2007Date of Patent: December 2, 2014Assignee: Gene Techno Science Co., Ltd.Inventors: Shigeyuki Kon, Chiemi Kimura, Toshimitsu Uede
-
Patent number: 8614296Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: April 24, 2009Date of Patent: December 24, 2013Assignee: Gene Techno Science Co., Ltd.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon, Toshimitsu Uede
-
Patent number: 8461310Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.Type: GrantFiled: February 12, 2009Date of Patent: June 11, 2013Assignees: Gene Techno Science Co., Ltd., National University Corporation Hokkaido UniversityInventors: Toshimitsu Uede, Yutaka Matsui
-
Patent number: 8372639Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.Type: GrantFiled: February 23, 2009Date of Patent: February 12, 2013Assignee: Gene Techno Science Co., Ltd.Inventors: Shigeyuki Kon, Toshimitsu Uede
-
Patent number: 8221754Abstract: The present invention relates to: an antibody, particularly a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening a compound which inhibits the activity of human ?9 integrin.Type: GrantFiled: July 11, 2007Date of Patent: July 17, 2012Assignee: Gene Techno Science Co., Ltd.Inventors: Masashi Kanayama, Daisuke Kurotaki, Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20110318368Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.Type: ApplicationFiled: February 23, 2009Publication date: December 29, 2011Inventors: Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20110091386Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: ApplicationFiled: April 24, 2009Publication date: April 21, 2011Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20110092575Abstract: The present invention provides siRNA for suppressing expression of human osteopontin in a more specific and strong manner, and a composition and a medicine comprising the same.Type: ApplicationFiled: June 6, 2008Publication date: April 21, 2011Inventor: Toshimitsu Uede
-
Publication number: 20110065899Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.Type: ApplicationFiled: October 25, 2007Publication date: March 17, 2011Inventors: Shigeyuki Kon, Chiemi Kimura, Toshimitsu Uede
-
Publication number: 20100317835Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.Type: ApplicationFiled: February 12, 2009Publication date: December 16, 2010Inventors: Toshimitsu Uede, Yutaka Matsui
-
Publication number: 20090252734Abstract: The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; a method for screening a compound which inhibits the activity of human ?9 integrin; and the like.Type: ApplicationFiled: July 11, 2007Publication date: October 8, 2009Inventors: Masashi Kanayama, Daisuke Kurotaki, Shigeyuki Kon, Toshimitsu Uede
-
Patent number: 7595045Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.Type: GrantFiled: January 12, 2006Date of Patent: September 29, 2009Assignee: Gene Techno Science Co., Ltd.Inventors: Daisuke Kurotaki, Masashi Kanayama, Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20080152653Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.Type: ApplicationFiled: January 12, 2006Publication date: June 26, 2008Inventors: Daisuke Kurotaki, Masashi Kanayama, Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20080069815Abstract: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.Type: ApplicationFiled: August 8, 2007Publication date: March 20, 2008Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., Astellas Pharma Inc.Inventors: Toshimitsu UEDE, Shigeyuki Kon, Yukihiko Saeki, Yasuyuki Yokosaki, Masaki Noda, Nobuchika Yamamoto
-
Publication number: 20070274993Abstract: The invention relates to an immunocompetent cell activation inhibitor comprising an antibody against OPN or peptide fragment thereof; a therapeutic agent for diseases attributed to immunocompetent cell activation comprising this inhibitor as an active ingredient; and a method of treatment with the use of the therapeutic agent. The invention provides a medical agent capable of treating diseases attributed to immunocompetent cell activation, such as hepatopathy, asthma, arthritis, diabetes, lupus, multiple sclerosis, arteriosclerosis and lung fibrosis.Type: ApplicationFiled: May 21, 2004Publication date: November 29, 2007Applicants: Immuno-Biological LAboratories Co., Ltd., Gene Techno ScienceInventors: Shigeyuki Kon, Toshimitsu Uede, Hongyan Diao
-
Patent number: 7241873Abstract: A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.Type: GrantFiled: September 25, 2002Date of Patent: July 10, 2007Assignees: Juridical Foundation the Chemo-sero-therapeutic Research Institute, Astellas Pharma Inc.Inventors: Toshimitsu Uede, Shigeyuki Kon, Nobuchika Yamamoto, Hirofumi Higuchi, Masaharu Torikai, Yoshiyuki Tokieda, Toshihiro Nakashima, Hiroaki Maeda
-
Publication number: 20060272040Abstract: The invention concerns a method for producing a mammal belonging to a non-human species made resistant by germinal transgenesis to an alpha-herpes virus mediated infection, for which the HveC or nectin-1 polypeptide constitutes a functional receptor. The method consists in introducing by insertion or homologous recombination into the genome of the cells constituting the mammal's germinal line, a transgene enabling expression of a chimeric protein consisting of an extracellular domain of nectin-1 or HveC or one of its parts and an immunoglobulin crystallzable fragment, in a suitable expression system.Type: ApplicationFiled: October 14, 2003Publication date: November 30, 2006Inventors: Etsuro Ono, Toshimitsu Uede